| Date | Title | Description |
| 31.01.2025 | Telix Completes Acquisition of Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform | MELBOURNE, Australia and INDIANAPOLIS, Jan. 31, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces it has completed the acquisition from antibody engineering company ImaginAb, Inc.... |
| 13.01.2025 | Telix Exceeds FY24 Guidance with US$142M Q4 Revenue | MELBOURNE, Australia and INDIANAPOLIS, Jan. 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today provides an update on its commercial and operational performance for the quarter ended 31 D... |
| 22.11.2022 | ImaginAb Executes New License and Supply Agreement for CD8 ImmunoPET Technology with TriSalus Life Sciences | LOS ANGELES, Nov. 22, 2022 /PRNewswire/ -- ImaginAb Inc., a global biotechnology company developing 89Zr crefmirlimab berdoxam (CD8 ImmunoPETTM) imaging agent and radiopharmaceutical therapy (RPT) products, is pleased to announce the signin... |
| 19.08.2021 | BriaCell Therapeutics : and ImaginAb Announce Collaboration to Evaluate Immunotherapy Imaging Technology in Advanced Breast Cancer | NEW YORK and VANCOUVER, British Columbia and LOS ANGELES, Aug. 19, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in ... |
| 19.08.2021 | BriaCell Therapeutics : to utilize ImaginAb's CD8 ImmunoPET imaging technology for whole body visualization of tumor-attacking CD8 T cells (Form 6-K) | BriaCell to utilize ImaginAb's CD8 ImmunoPET imaging technology for whole body visualization of tumor-attacking CD8 T cells
NEW YORK and VANCOUVER, British Columbia and LOS ANGELES, Aug. 19, 2021-BriaCell Therapeutics Corp. (Nasdaq: BCTX, B... |
| 23.07.2021 | ImaginAb Announces Extension Of Long-Standing Partnership With Boehringer Ingelheim | |
| 07.06.2021 | ImaginAb Aims to Help Our Immune Systems Better Detect Late-Stage Cancer | Cancer drugs have come a long way in treating late-stage patients, and one company is betting its technology can make them even more effective.
ImaginAb, the Inglewood-based cancer immunotherapy company, announced last week that it raised $... |
| 04.06.2021 |
ImaginAB Gets $12.8M
| Los Angeles-based ImaginAb, a biotechnology company which is developing radiopharmaceutical imaging and therapy agents, has raised $12.8M in a funding round, the company said on Thursday. According to the company, the funding was led by Ada... |
| 07.01.2021 | ImaginAb Announces License and Supply Agreement with Pfizer for CD8 ImmunoPET Technology | |
| 10.10.2017 |
ImaginAb Finds $8M For Immunotherapy Imaging
| Inglewood-based ImaginAb, which is developing a cell imaging agent used for imaging changes in cell tumors, has raised $8M in a funding round, the firm said on Monday. The funding was led by Adage Capital, and also included the Parker Insti... |
| 10.10.2017 | Term Sheet — Tuesday, October 10 | BIG MONEY, FEW DEALS
Good morning, Term Sheet readers.
Paid Content How can you protect what you can't see? From ExtraHop
But here’s the twist. Investors are pumping larger amounts of capital into fewer companies. In other words, a small pe... |
| 09.10.2017 | ImaginAb Closes $8M in New Funding |
INGLEWOOD, CA, Immuno-oncology imaging company, has raised an additional $8 million in new equity funding led by Adage Capital.
>> Click here for more funding data on ImaginAb
>> To export ImaginAb funding data to PDF and Ex... |
| 09.10.2017 | ImaginAb Closes $8M Funding Round | ImaginAb, an Inglewood, CA-based immuno-oncology imaging company, raised an additional $8m in equity funding.
The round was led by Adage Capital, with participation from the Parker Institute for Cancer Immunotherapy, NVF, Cycad Group, Nexte... |
| 09.10.2017 | Adage Capital Leads $8M Funding for ImaginAb | ImaginAb, an immuno-oncology imaging company, has raised an additional $8 million in new equity funding led by Adage Capital. The company's shareholders also include the Parker Institute for Cancer Immunotherapy, NVF, Cycad Group, Nextech I... |
| 09.10.2017 | Sean Parker's Institute Backs Cancer Firm ImaginAb's $8M Funding Round | - |
| 09.10.2017 | Adage Capital Leads $8M Funding for ImaginAb | ImaginAb, an immuno-oncology imaging company, has raised an additional $8 million in new equity funding led by Adage Capital. The company's shareholders also include the Parker Institute for Cancer Immunotherapy, NVF, Cycad Group, Nextech I... |
| 09.10.2017 | Sean Parker’s Institute Backs Cancer Firm ImaginAb’s $8M Funding Round | - |
| 21.05.2014 | California payer one of 9 healthcare companies on RedHerring Top 100 list | Last year the company did a study of 120,000 employees enrolled in its program over a 3-year period. SeeChange reported these results:
Close to 80% of the incentive program members earned points, with slightly increased and sustained engage... |
| 11.05.2014 | ImaginAb Raises $21M in Series B Funding | ImaginAb, an Inglewood, CA-based clinical stage biotech company, raised $21m in Series B funding.
The round was led by Mérieux Développement, with participation from Novartis Venture Funds, Cycad Group and Nextech Invest.
The company intend... |
| 09.05.2014 | ImaginAb Concludes $21M Series B |
LOS ANGELES, CA, Clinical stage biotechnology company announced today the completion of a $21M Series B financing.
>> Click here for more funding data on ImaginAb
>> To export ImaginAb funding data to PDF and Excel, click he... |
| 09.05.2014 | ImaginAb Raises $21 Million | - |
| 09.05.2014 |
ImaginAb Raises $21M
| Los Angeles-based ImagineAb, a developer of biotechnology used for molecular imaging, said Thursday that it has raised $21M in a Series B financing round. The funding was led by Merieux Developpement, and also included Novartis Venture Fund... |
| 27.03.2012 |
ImaginAb Raises $12.5M
| Los Angeles-based ImaginAb, a UCLA spinout which is developing antibody fragments for use in the diagnostic imaging market, said late last night that it has raised $12.5M in a Series A financing round. The round was led by Novartis Venture ... |
| 27.03.2012 | ImaginAb Completes Series A |
LOS ANGELES, CA, Clinical-stage company developing in vivo imaging agents for Positron Emission Tomography (PET) based on antibody fragment technology, announced the completion of a Series A financing, led by Novartis Venture Funds.
>... |
| 27.03.2012 | ImaginAb Completes $12.5M Series A Financing | ImaginAb, Inc., a Los Angeles, CA-based clinical-stage company developing in vivo imaging agents for Positron Emission Tomography (PET) based on antibody fragment technology, completed a $12.5m Series A financing.
The round was led by Novar... |
| 27.03.2012 | Biotech Start-up ImaginAb Raises Nearly $13 Million | - |
| - | California payer one of 9 healthcare companies on RedHerring Top 100 list | SeeChange Health has won a Red Herring Top 100 North America Award. The award recognizes private companies from North America for innovation and new technology in their respective industries.
SeeChange Health offers Health Insurance and Hea... |
